Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis

Hepatology

Volumn 66, Issue 1, 2017, Pages 13-26

  Chen, Guofeng ^a,b   Wang, Cheng ^a,c,d   Chen, Jing ^a,c   Ji, Dong ^a,b   Wang, Yudong ^a,c   Wu, Vanessa ^a,c   Karlberg, Johan ^c   Lau, George ^a,b,c,e  

^a Beijing 302 Hong Kong Humanity and Health Hepatitis C Diagnosis and Treatment Centre   (China)

^b BEIJING 302 HOSPITAL   (China)

^c Humanity and Health Research Centre   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e Humanity and Health Medical Centre   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; INTERFERON; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; META ANALYSIS; MIXED INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROCONVERSION; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; VIRUS REACTIVATION; COINFECTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; FEMALE; HEPACIVIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; MALE; PROGNOSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; MALE; PROGNOSIS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 85017518282     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29109     Document Type: Article

References (50)

1. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081-1088.
2. Jamma S, Hussain G, Lau DTY. Current concepts of HBV/HCV coinfection: coexistence, but not necessarily in harmony. Curr Hepat Rep 2010;9:260-269.
3. Yu G, Chi X, Wu R, Wang X, Gao X, Kong F, et al. Replication inhibition of hepatitis B virus and hepatitis C virus in co-infected patients in Chinese population. PLoS One 2015;10:e0139015.
4. Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015;61:1304-1306.
5. Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep 2015;9:164.
6. Ou PC, Fang ZX, Chen J. Hepatitis B reactivation in a chronichepatitis C patient treated with ledipasvirand sofosbuvir: a case report. Clin Res Hepatol Gastroenterol 2016; doi: 10.1016/j.clinre.2016.08.001.
7. Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res 2016;46:489-491.
8. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of HBV in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2017;15:132-136.
9. European Medicines Agency. PRAC warns of risk of hepatitis B re-activation with direct- acting antivirals for hepatitis C. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Direct-acting_antivirals_for_hepatitis_C_20/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500217495.pdf. Published December 2, 2016. Accessed December 5, 2016.
10. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM523499.pdf. Published October 4, 2016. Accessed December 5, 2016.
11. American Association for the Study of Liver Disease, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://hcvguidelines.org/sites/default/files/HCV-Guidance_October_2016_a.pdf. Published July 6, 2016. Accessed December 5, 2016.
12. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. 2016. J Hepatol 2017;66:153-194.
13. Chuang WL, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005;10:125-133.
14. Erol S, Ozkurt Z, Ozbek A, Parlak M. Poor response to treatment with Peg-IFN containing regimens in patients coinfected with hepatitis B and hepatitis C virus. Hepat Mon 2009;9:224-228.
15. Vigano M, Aghemo A, Iavarone M, Rumi MG, Agnelli F, Lampertico P, et al. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. Antivir Ther 2009;14:789-796.
16. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009;136:496-504.
17. Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, et al. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antivir Ther 2011;16:959-968.
18. Villa E, Grottola A, Trande P, Seium Y, Rebecchi AM, Dugani A, et al. Reactivation of hepatitis B virus infection induced by interferon (IFN) in HBsAg-positive, antiHCV-positive patients. Lancet 1993;341:1413.
19. Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008;49:688-694.
20. Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009;29:1485-1493.
21. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001;96:2973-2977.
22. Yalcin K, Degertekin H. A 12-month course of combination therapy with interferon-alpha and ribavirin in chronic hepatitis due to coinfection with hepatitis B and C viruses. Clin Drug Invest 2002;22:797-798.
23. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003;37:568-576.
24. Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800.
25. Saitta C, Pontisso P, Brunette MR, Fargion S, Gaeta GB, Niro GA, et al. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy. Antivir Ther 2006;11:931-934.
26. Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, et al. Chronic hepatitis C responds poorly to combination therapy in chronic hepatitis B carriers. Neth J Med 2008;66:191-195.
27. Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection. J Gastroenterol Hepatol 2010;25:259-263.
28. Kim YJ, Lee JW, Jeong SH, Kim YS, Yim HJ, Kim BH, et al. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol 2011;17:199-205.
29. Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV-infection in patients coinfected with HBV. Antivir Ther 2016;21:605-609.
30. Yeh ML, Hsieh MY, Huang CI, Huang CF, Hsieh MH, Huang JF, et al. Long-term efficacy of peg-interferon/ribavirin with and without lamivudine therapy for HBeAg-positive hepatitis B and C dual infection. J Gastroenterol Hepatol 2016;31:835-841.
31. Yeh ML, Hsieh MY, Huang CI, Huang CF, Hsieh MH, Liang PC, et al. Personalized therapy of chronic hepatitis C and B dually infected patients with pegylated interferon plus ribavirin: a randomized study. Medicine (Baltimore) 2015;94:e1837.
32. Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995;2:39-45.
33. Zignego AL, Fontana R, Puliti S, Barbagli S, Monti M, Careccia G, et al. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol 1997;142:535-544.
34. Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999;58:201-207.
35. Guptan RC, Thakur V, Raina V, Sarin SK. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 1999;14:893-898.
36. Myers RP, Thibault V, Poynard T. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. J Viral Hepat 2003;10:103-110.
37. Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P, et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004;29:160-166.
38. Hasegawa I, Orito E, Tanaka Y, Hirashima N, Sakakibara K, Sakurai M, et al. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int 2005;25:247-253.
39. Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 2007;79:1075-1081.
40. Aygen B, Gunal O, Yildiz O, Celen MK, Akhan S, Barut S, et al. Hepatitis B virus and hepatitis C virus coinfection: an evaluation of 82 patients in Turkey. Hepatol Int 2013;7:S187-S188.
41. Liaw YF, Chien RN, Lin SM, Yeh CT, Tsai SL, Sheen IS, et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997;17:449-452.
42. Rautou PE, Asselah T, Saadoun D, Martinot M, Valla D, Marcellin P. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. Eur J Gastroenterol Hepatol 2006;18:1019-1022.
43. Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Nishimura D, et al. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol 2016;9:252-256.
44. Wiegand SB, Jaroszewicz J, Potthoff A, Honer Zu Siederdissen C, Maasoumy B, Deterding K, et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-gamma-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect 2015;21:710, e711–e719.
45. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
46. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702-726.
47. Yan LB, Rao HY, Ma YJ, Bai L, Chen EQ, Du LY, et al. Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study. BMJ Open 2016;6:e012016.
48. Bersoff-Matcha SJ, Cao KY, Jason M, Ajao A, Jones SC, Meyer T, et al. Hepatitis B reactivation associated with direct acting antiviral therapy for hepatitis C: a review of spontaneous post-marketing cases. In: Annual Meeting of the American Association for the Study of Liver Diseases, 2016; November 11-15, 2016; Boston, Massachusetts. 2016.
49. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749.
50. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-219.